Shenglin Ma

Years Active: 2023-2023
Publications (10 Years): 2

This page only lists publications with an associated author ORCID identifier.

Publications

Shengxiang Ren, Jifeng Feng, Shenglin Ma, HuaJun Chen, Zhiyong Ma, Cheng Huang, Li Zhang, Jianxing He, Changli Wang, Jianying Zhou, Pongwut Danchaivijtr, Chin-Chou Wang, Ihor Vynnychenko, Kai Wang, Francisco Orlandi, Virote Sriuranpong, Ben Li, Jun Ge, Thao Dang, Cai-Cun Zhou
KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC. International journal of cancer (2023)
Shengxiang Ren, Jifeng Feng, Shenglin Ma, HuaJun Chen, Zhiyong Ma, Cheng Huang, Li Zhang, Jianxing He, Changli Wang, Jianying Zhou, Pongwut Danchaivijtr, Chin-Chou Wang, Ihor Vynnychenko, Kai Wang, Francisco Orlandi, Virote Sriuranpong, Ben Li, Jun Ge, Thao Dang, Cai-Cun Zhou
KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC. International journal of cancer (2023)

Shenglin Ma.css-eqlu8i{font-size:small;padding-left:4px;}